The Europe Colorectal Cancer Screening Market should witness market growth of 4.4% CAGR during the forecast period (2023-2030).
Demand for colorectal cancer therapy is anticipated to rise significantly over time as the prevalence of colorectal cancer rises. Leading providers of colorectal cancer diagnostics are concentrating on developing efficient and optimal diagnostic solutions because they are essential to the disease's treatment. The diagnosis of colorectal cancer relies heavily on screening and imaging to determine the extent of the tumor-affected area. In the coming years, there will likely be a significant increase in demand for in-vitro diagnostics for colorectal cancer screening.
The market is expanding significantly because of increasing awareness regarding colorectal cancer early detection. The early stages of colorectal cancer are being detected and monitored using a variety of screening and diagnostic methods, such as colonoscopy and biomarker testing. Technological developments and stakeholder collaborations are driving market expansion. Improving screening accuracy, sensitivity, and specificity are priorities to improve patient outcomes. The market is expected to experience significant growth owing to rising incidence rates and continuous research, which will enhance patient treatment and lower mortality rates.
In the United Kingdom, the government offers bowel cancer screening every two years to men and women aged 60 to 74. The elderly can request a screening kit every two years by calling the free helpline. In addition, ministers agreed in August 2018 that the screening age for bowel cancer in England will increase to 50. From April 2021, the National Health Service (NHS) lowered the age range for bowel cancer screenings. This regional market is anticipated to expand due to the aging populations in European nations and the government's favourable attitude toward cancer screening.
The Germany market dominated the Europe Colorectal Cancer Screening Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,392.4 million by 2030. The UK market is estimated to witness a CAGR of 3.5% during (2023-2030). Additionally, The France market would showcase a CAGR of 5.2% during (2023-2030).
Based on Type, the market is segmented into Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG).
Demand for colorectal cancer therapy is anticipated to rise significantly over time as the prevalence of colorectal cancer rises. Leading providers of colorectal cancer diagnostics are concentrating on developing efficient and optimal diagnostic solutions because they are essential to the disease's treatment. The diagnosis of colorectal cancer relies heavily on screening and imaging to determine the extent of the tumor-affected area. In the coming years, there will likely be a significant increase in demand for in-vitro diagnostics for colorectal cancer screening.
The market is expanding significantly because of increasing awareness regarding colorectal cancer early detection. The early stages of colorectal cancer are being detected and monitored using a variety of screening and diagnostic methods, such as colonoscopy and biomarker testing. Technological developments and stakeholder collaborations are driving market expansion. Improving screening accuracy, sensitivity, and specificity are priorities to improve patient outcomes. The market is expected to experience significant growth owing to rising incidence rates and continuous research, which will enhance patient treatment and lower mortality rates.
In the United Kingdom, the government offers bowel cancer screening every two years to men and women aged 60 to 74. The elderly can request a screening kit every two years by calling the free helpline. In addition, ministers agreed in August 2018 that the screening age for bowel cancer in England will increase to 50. From April 2021, the National Health Service (NHS) lowered the age range for bowel cancer screenings. This regional market is anticipated to expand due to the aging populations in European nations and the government's favourable attitude toward cancer screening.
The Germany market dominated the Europe Colorectal Cancer Screening Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,392.4 million by 2030. The UK market is estimated to witness a CAGR of 3.5% during (2023-2030). Additionally, The France market would showcase a CAGR of 5.2% during (2023-2030).
Based on Type, the market is segmented into Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG).
Scope of the Study
By Type
- Colonoscopy
- Stool-based
- Fecal Immunochemical Test (FIT)
- Fecal Occult Blood Test (FOBT)
- Stool-DNA Test
- Others
By End-user
- Hospitals & Clinics
- Clinical Laboratories
- Diagnostic Imaging Centres
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Novigenix SA
- Eiken Chemical Co., Ltd.
- Clinical Genomics Pathology, Inc.
- Exact Sciences Corporation
- Epigenomics AG
- BioMerieux S.A.
- Olympus Corporation
- Sysmex Corporation
- Fujifilm Holdings Corporation
- Siemens Healthineers AG (Siemens AG)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Colorectal Cancer Screening Market by Type
Chapter 6. Europe Colorectal Cancer Screening Market by End-user
Chapter 7. Europe Colorectal Cancer Screening Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Novigenix SA
- Eiken Chemical Co., Ltd.
- Clinical Genomics Pathology, Inc.
- Exact Sciences Corporation
- Epigenomics AG
- BioMerieux S.A.
- Olympus Corporation
- Sysmex Corporation
- Fujifilm Holdings Corporation
- Siemens Healthineers AG (Siemens AG)
Methodology
LOADING...
